Open AccessAtezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma
Author(s) -
Hayato Kawachi,
Kei Kunimasa,
Yoji Kukita,
Harumi Nakamura,
Keiichiro Honma,
Takahisa Kawamura,
Tomio Inoue,
Motohiro Tamiya,
Hanako Kuhara,
Kazumi Nishino,
Yu Mizote,
Takashi Akazawa,
Hideaki Tahara,
Toru Kumagai
Publication year - 2021
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2020-0311
Subject(s) - carboplatin , bevacizumab , medicine , atezolizumab , oncology , paclitaxel , chemotherapy , lung cancer , cancer , immunotherapy , cisplatin , nivolumab
SMARCA4-deficient thoracic sarcoma (DTS) is a recently noted progressive thoracic malignancy. We recently experienced three cases of SMARCA4-DTS who were treated with atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (ABCP) as the first-line therapy. Immunohistopathological analysis revealed absent expression of SMARCA4 in all cases. The tumor mutational burden was over 11/Mb and mutations in SMARCA4 and TP53 were detected in all three cases. Partial response to ABCP treatment was observed in all three cases, with a progression-free survival of approximately 6 months or longer and a continuous response of 1 year or longer in one case. The first-line ABCP treatment demonstrated durable efficacy in SMARCA4-DTS regardless of the degree of PD-L1 expression.